ULTOMIRIS (ravulizumab) treatment of atypical hemolytic uremia syndrome (aHUS): CHMP gives positive reviews
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Alexion Pharmaceuticals recently announced that the European Medicines Agency's Human Drug Commission (CHMP) has taken a positive approach, recommending the EUROPEAN Union approval of ULTOMIRIS (ravulizumab) marketing license for the treatment of patients with the following diseases: patients who have not received complementary inhibitors, or have been treated with SOLIRIS (eculib) for at least 3 months and have a monoantitic reaction to atypical hemolytic uremia syndrome (aHUS)aHUS is a rare disease that can cause sexual damage to major organs (mainly the kidneys) by damaging the walls of blood vesselsaHUS affects adults and children, and many patients in critical condition often need supportive treatment in the intensive care unit, including dialysisIn many cases, the prognosis of aHUS may be poor, so timely and accurate diagnosis is essential to improve patient prognosisDr John Orloff, Executive Vice President and Head of Research and Development at Alexion, said, "If approved in Europe, ULTOMIRIS will be the first and only long-acting C5 inhibitor for patients with aHUSThe consequences of aHUS are severe and can be devastating, including persistent life-threatening and complicationsFor aHUS patients and their families, this presents great uncertainty and challenges."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
